Tag : ATRIAL FIBRILLATION

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, affecting up to 6.1 million individuals in the United States (US) and an estimated 50 million globally as of 2020. As a major contributor to stroke risk, AF is responsible for one in every seven strokes and is often more severe compared to other etiologies. Early detection of AF is crucial for stroke prevention, yet despite its impact, widespread screening is not yet universally recommended. Researchers are exploring various approaches, including the Heartline Study, which seeks to investigate the role of wearable technology in identifying AF early and preventing stroke.

Atrial fibrillation (AF) is a complex condition, extending beyond a simple rhythm abnormality. It is associated with an increased risk of cognitive impairment, all-cause dementia, vascular dementia and Alzheimer’s disease. This has been linked to silent strokes that gradually impair brain function, as well as cerebral hypoperfusion resulting from the irregular rhythm and subsequent reduction in cardiac output. Furthermore, the persistently high mortality rates in AF patients, despite advancements in treatment modalities, underscore the importance of prioritizing primary prevention.

Direct oral anticoagulants (DOACs) have revolutionized the management of atrial fibrillation (AF), significantly reducing the risk of ischemic stroke.